SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3557 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3107It's about time!CuttingEdge Bio-9/29/2020
3106A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With NonalcoholiBiotechwantabe19/29/2020
3105Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragmentsBiotechwantabe-9/29/2020
3104There was P1b, I post a link. Formulation issue...I agree, hard to control. WillMiljenko Zuanic-9/28/2020
3103I presume it works in animal models, but I'm not aware of any PoC in humans.DewDiligence_on_SI-9/28/2020
3102Some posters on my Twitter stream claim the formulation issue is intractable.DewDiligence_on_SI-9/28/2020
3101<Twenty-eight percent of patients had incomplete aggregation of GB-102 and haMiljenko Zuanic-9/28/2020
3100Did anyone try Sunitinib to show that it does work in AMD?Miljenko Zuanic-9/28/2020
3099GRAY IPO: investorshub.advfn.comDewDiligence_on_SI-9/25/2020
3098Exactly IL6 beat TNFa (https://acrabstracts.org/abstract/efficacy-and-safety-of-Felix B-9/24/2020
3097Considering this is as good as keytruda but second to market, would assume regenBiotechwantabe-9/21/2020
3096Looks at least as good to me. What are you referring to? pubmed.ncbi.nlm.nih.gCuttingEdge Bio-9/21/2020
3095Libtayo mono Not sure how stats compares to KeytrudaBiotechwantabe-9/21/2020
3094What do you make of the recent lily data? The lack of a dose response is quite Felix B-9/19/2020
3093Not bad, preclinical data looks good!Miljenko Zuanic-9/14/2020
3092Il4/13/pd-1Biotechwantabe19/11/2020
3091That would be very good (and quick) option.Miljenko Zuanic-8/25/2020
3090<<(as prophylactic, few days dosing to rise nAbs level to a therapeutic onmouton29-8/24/2020
3089This Times article from the 14th reports on the slow enrollment and says that bomouton29-8/24/2020
3088Unless they improved on antibody mediated viro-toxicity (or viral killing)?Miljenko Zuanic-8/24/2020
3087I'm a little confused here. How are they magically creating a formulation tCuttingEdge Bio-8/24/2020
3086Yes, indeed it is significant. First, other covid nAbs developers do not have SMiljenko Zuanic-8/22/2020
3085Thanks, I didn’t notice that. Was wondering why they didn’t go with sc; but IBiotechwantabe-8/22/2020
3084BIG difference, SC versus iv route of administration...GAME CHANGER, if it work!Miljenko Zuanic18/21/2020
3083Regn-cov-2 another trial Chronic - multi dose.Biotechwantabe-8/21/2020
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News